Loading...
OTCM
THOXF
Market cap87mUSD
Jun 26, Last price  
0.29USD
Name

Bioporto A/S

Chart & Performance

D1W1MN
P/E
—
P/S
26.26
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.69%
Rev. gr., 5y
3.54%
Revenues
36m
+17.07%
4,362,0005,554,0008,340,0008,340,00011,008,00013,802,00018,584,00017,858,00016,625,00018,706,00020,383,00020,720,00025,155,00026,016,00026,622,00023,204,00024,254,00028,969,00030,958,00036,243,000
Net income
-68m
L+21.15%
-15,712,000-16,985,000-15,246,000-14,264,000-16,078,000-14,300,000-14,906,000-14,700,000-20,623,000-12,926,000-10,732,000-22,800,000-32,243,000-38,048,000-69,642,000-61,562,000-57,113,000-75,923,000-56,328,000-68,243,000
CFO
-84m
L+50.72%
-13,881-13,456-14,129,000-13,717,000-13,286,000-13,379,000-13,606,000-15,280,000-16,640,000-16,138,000-16,574,000-19,660,000-29,399,000-38,009,000-60,164,000-35,616,000-64,577,000-52,485,000-55,456,000-83,583,000
Earnings
May 06, 2025

Profile

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
URL
https://bioporto.com/
IPO date
Jan 02, 1985
Employees
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
36,243
17.07%
30,958
6.87%
28,969
19.44%
Cost of revenue
111,695
91,122
107,913
Unusual Expense (Income)
NOPBT
(75,452)
(60,164)
(78,944)
NOPBT Margin
Operating Taxes
(5,500)
(4,879)
(5,624)
Tax Rate
NOPAT
(69,952)
(55,285)
(73,320)
Net income
(68,243)
21.15%
(56,328)
-25.81%
(75,923)
32.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
81,400
46,157
92,737
BB yield
-12.94%
-6.16%
-12.07%
Debt
Debt current
3,344
2,970
3,197
Long-term debt
19,036
11,530
18,093
Deferred revenue
Other long-term liabilities
Net debt
(37,284)
(54,630)
(60,502)
Cash flow
Cash from operating activities
(83,583)
(55,456)
(52,485)
CAPEX
(350)
(39)
(471)
Cash from investing activities
1,187
(277)
(503)
Cash from financing activities
75,466
40,790
88,699
FCF
(83,685)
(52,945)
(63,563)
Balance
Cash
59,664
66,402
81,792
Long term investments
2,728
Excess cash
57,852
67,582
80,344
Stockholders' equity
68,830
60,160
70,455
Invested Capital
21,116
7,250
10,331
ROIC
ROCE
EV
Common stock shares outstanding
405,763
358,498
331,202
Price
1.55
-25.84%
2.09
-9.91%
2.32
-6.07%
Market cap
628,933
-16.06%
749,261
-2.49%
768,388
11.88%
EV
591,649
694,631
708,120
EBITDA
(73,070)
(57,486)
(74,978)
EV/EBITDA
Interest
453
642
1,088
Interest/NOPBT